Abivax (ABVX) Income from Continuing Operations: 2022-2025
Historic Income from Continuing Operations for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to -$54.8 million.
- Abivax's Income from Continuing Operations fell 31.26% to -$54.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$151.6 million, marking a year-over-year decrease of 71.69%. This contributed to the annual value of -$188.3 million for FY2024, which is 18.48% down from last year.
- Latest data reveals that Abivax reported Income from Continuing Operations of -$54.8 million as of Q2 2025, which was up 0.52% from -$55.1 million recorded in Q1 2025.
- In the past 5 years, Abivax's Income from Continuing Operations ranged from a high of -$66.11 in Q4 2022 and a low of -$55.1 million during Q1 2025.
- For the 3-year period, Abivax's Income from Continuing Operations averaged around -$33.0 million, with its median value being -$44.2 million (2024).
- Data for Abivax's Income from Continuing Operations shows a maximum YoY tumbled of 107.34% (in 2023) over the last 5 years.
- Quarterly analysis of 4 years shows Abivax's Income from Continuing Operations stood at -$66.11 in 2022, then crashed by 107.34% to -$137.07 in 2023, then tumbled by 34.79% to -$184.76 in 2024, then crashed by 31.26% to -$54.8 million in 2025.
- Its Income from Continuing Operations stands at -$54.8 million for Q2 2025, versus -$55.1 million for Q1 2025 and -$184.76 for Q4 2024.